Reports Q2 revenue $76.5M, consensus $78.78M. “The submission of our supplemental Biologics License Application for Afrezza in pediatric patients is a meaningful milestone for MannKind (MNKD) and people living with diabetes,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “In our orphan lung pipeline, we’re encouraged by the robust enrollment progress in the ICoN-1 trial of inhaled clofazimine for NTM lung disease, and we are excited to advance nintedanib DPI into Phase 2 for IPF.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- Is MNKD a Buy, Before Earnings?
- MannKind Corporation’s Global Supply Chain Risks: Navigating Trade Policies and Financial Challenges
- MannKind’s Growth Potential Bolstered by United Therapeutics Partnership and Promising Pipeline
- MannKind price target lowered to $8 from $10 at RBC Capital
- MannKind assumed with a Buy at H.C. Wainwright